ProCE Banner Activity


Aggressive B-Cell Lymphomas: Experts Discuss New Care Standards and Evolving Treatment Strategies


Watch this on-demand webcast from a December 2022 symposium featuring John P. Leonard, MD; John Allan, MD; and Laurie H. Sehn, MD, MPH, on the use of new and evolving treatment strategies in the management of patients with mantle cell lymphoma and diffuse large B-cell lymphoma.

Physicians: Maximum of 2.00 AMA PRA Category 1 Credits

Released: January 30, 2023

Expiration: January 29, 2024

No longer available for credit.



John P. Leonard

John P. Leonard, MD

Senior Associate Dean for Innovation and initiatives
Chair (Interim), Weill Department of Medicine
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Weill Cornell Medicine/NewYork-Presbyterian
New York, New York

John N. Allan

John N. Allan, MD

Associate Professor of Clinical Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

Laurie H. Sehn

Laurie H. Sehn, MD, MPH

Chair, Lymphoma Tumour Group
BC Cancer
Vancouver, Canada

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from

Bristol Myers Squibb

Genmab US Inc and AbbVie

Karyopharm Therapeutics Inc.

Regeneron Pharmaceuticals, Inc.

Target Audience

This educational program is intended for medical oncologists and other healthcare professionals who treat patients with B cell lymphomas.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in selecting individualized treatments for patients with MCL and DLBCL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Interpret expert-recommended molecular profiling for appropriate patients with MCL and DLBCL to guide therapy selection

  • Select treatment regimens for patients with MCL and DLBCL based on available clinical data, disease characteristics, and individual patient goals and preferences to optimize clinical outcomes
  • Identify patients with aggressive B-cell lymphoma who would likely benefit from enrollment on a clinical trial
  • Plan optimal supportive care measures to manage adverse events associated with newer therapeutic regimens used in the treatment of MCL and DLBCL


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

John P. Leonard, MD: consulting/advisor/speaker: AbbVie, Astellas, AstraZeneca, Bayer, BeiGene, Bristol-Myers Squibb, Calithera,

John Allan, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Epizyme, Genentech, Janssen, Pharmacyclics.

Laurie H. Sehn, MD, MPH: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Bristol-Myers Squibb/Celgene, Gilead/Kite, Incyte, Janssen, Merck, Roche/Genentech, Seattle Genetics, Teva, TG Therapeutics.

Planner/Manager Text

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Learner wishing to earn CE/CME credit must: 

  1. View the content in its entirety
  2. Relate the content material to the learning objectives 
  3. Complete evaluation form 

The estimated time to complete this activity is 2.0 hours.